Premium
Traditional Chinese medicine may be further explored as candidate drugs for pancreatic cancer: A review
Author(s) -
Gao Yue,
Chen Shiyu,
Sun Jiayi,
Su Siyu,
Yang Dong,
Xiang Li,
Meng Xianli
Publication year - 2021
Publication title -
phytotherapy research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.019
H-Index - 129
eISSN - 1099-1573
pISSN - 0951-418X
DOI - 10.1002/ptr.6847
Subject(s) - pancreatic cancer , gemcitabine , medicine , traditional chinese medicine , oncology , survival rate , cancer , chemotherapy , drug , radiation therapy , disease , traditional medicine , pharmacology , alternative medicine , pathology
Pancreatic cancer is a disease with a high mortality rate. Although survival rates for different types of cancers have improved in recent years, the five‐year survival rate of pancreatic cancer stands at 8%. Moreover, the current first‐line therapy, gemcitabine, results in low remission rates and is associated with drug resistance problems. Alternative treatments for pancreatic cancer such as surgery, chemotherapy and radiation therapy provide marginal remission and survival rates. This calls for the search of more effective drugs or treatments. Traditional Chinese medicine contains numerous bioactive ingredients some of which show activity against pancreatic cancer. In this review, we summarize the mechanisms of five types of traditional Chinese medicine monomers. In so‐doing, we provide new potential drug candidates for the treatment of pancreatic cancer.